News & Events

HTG Molecular Expands Agreement with Illumina to Include Autoimmune, Cardiovascular, and Fibrosis Disorders and Diseases

Amendment allows for the development of IVD test kits compatible with Illumina technology TUCSON, Ariz. , April 30, 2019 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has amended its

full press release

Posted on:

Return To List

Page last updated